Cursos

Actividades Académicas
Atrás

XV International School of Pharmacology «Teófilo Hernando». Alzheimer's and other neurodegenerative diseases: Pharmaco-therapeutic advances

Información General

Programa curso

Becarios

Listado resolución becas
Código
62Y4
Horas
30
Fecha
25 Jul 2016
29 Jul 2016
Precio
130 € Tarifa A
Tipo
Escuela
Temática
Medicina y Ciencias de la Salud
ECTS
1

Sede donde se gestiona

Santander

Lugar de impartición

Santander - Península de la Magdalena (Rector Ernest Lluch)

Dirección

Antonio G. García
Professor of Pharmacology
Teófilo Hernando's Institute for Drug Discovery
Medical School, Autonomous University of Madrid, Spain


Michael Duchen
Professor of Physiology
Department of Cell and Development Biology
University College London, UK


Secretaría

Luis Gandía
Professor of Pharmacology
Teófilo Hernando's Institute for Drug Discovery
Medical School, Autonomous University of Madrid, Spain


COLABORACIÓN


COLABORACIÓN

Descripción de la actividad

THE "TEÓFILO HERNANDO'S" SCHOOL OF PHARMACOLOGY: ORIGIN, DEVELOPMENT AND ACTIVITIES

The Teófilo Hernando’s School of Pharmacology (THSP) was initiated in 1996, in the frame of the summer courses of the UIMP. At that time, Rector José Luis García Delgado invited professor Antonio G. García (Autonomous University of Madrid) to organise this School. The courses are held at the magnificent Palace of la Magdalena, located on top of a hill at the Peninsula of La Magdalena.  

The format of a UIMP’s School (“Escuela”) is based in the critical analysis in the frontier of knowledge of a given scientific topic, along a week (Monday to Friday) by scientists and students of all over the world. Emphasis is always made in drug discovery and development as well in basic research that illuminate on the identification of new biological drug targets for treating disease. The THSP was named after Teófilo Hernando, a Spanish MD/PhD pharmacologist who was trained under Oswald Schmiedeberg at Strassbourg, the first formal Pharmacology School where many pharmacologists were trained at the beginning of the XX century and then developed the subject of basic and clinical pharmacology all over the world. Teófilo Hernando introduced pharmacology as an independent teaching and science subject at the Central University of Madrid, along the first four decades of the XX century. He trained numerous other disciples that extended the subject to many other Spanish universities along the XX century. 

Since 1996, 13 editions of the THSP have been held. Over 100 internationally recognised scientist professors and over 500 students have since then attended the THSP. The subjects of the subsequent schools were as follows: 

1.-Drugs and their receptors (1996)

2.-Drugs for the brain (1997)

3.-Clinical trials in Spain (2000)

4.-Biotechnological drugs (2001)

5.-Alzheimer’s disease (2002)

6.-Drugs and cardiovascular risk (2003)

7.-Chronic inflammation and osteoarthritis (2008)

8.-Neurodegenerative diseases (2009)

9.-The language of neurons (2010)

10.-Neuroprotection and neuroreparation of the injured brain (2011)

11.-New concepts and strategies for neuroprotection (2012)

12.-Brain damage and repair (2013)

13.-Frontier drug discovery in brain disease (2014)

14.-New therapeutic targets in brain disease (2015)

FORMAT OF YOUNG RESEARCHER COMMUNICATIONS 

Young Researcher Communications (YRCs; every afternoon from Monday to Thursday) are coordinated by scientists with expertise in the subject, which are also responsible for recruiting the six young researchers of each session, either PhD students or postdocs.  

The YRC session consists in a 30-min general introduction on the topic, done by the coordinator and six 10-min communications followed by 5-min discussion presented by postdocs and PhD students; thus, each session will be developed in 2 hours sharp. 

The session themes must be related with the course subject namely neuroscience, physiology, neurology, psychiatry and pharmacology of the CNS with a broad scope. It is convenient to put some emphasis in potential drug targets for specific diseases (this is a School of Pharmacology) although this is not a restrictive condition at all. 

Registration and participation in the entire course is mandatory for the coordinating scientists and the young scientists participating in these YRCs. The Teófilo Hernando’s Foundation and UIMP will help with expenses on an individual basis. It is, however, desirable that some funds from the working institution of the postdocs and PhD students may be provided to cover some of the travel and local expenses at Santander.

 

Participantes

DIRECCIÓN

Michael Duchen
Professor of Physiology
Department of Cell and Development Biology
University College London, UK

Antonio G. García
Professor of Pharmacology
Teófilo Hernando's Institute for Drug Discovery
Medical School, Autonomous University of Madrid, Spain

SECRETARÍA

Luis Gandía
Professor of Pharmacology
Teófilo Hernando's Institute for Drug Discovery
Medical School, Autonomous University of Madrid, Spain

PARTICIPANTES

Andrés Mateo Baraibar Sierra
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Marta Bolós Jurado
Molecular Neurobiology Department
Centro de Biología Molecular "Severo Ochoa"

Izaskun Buendía Abaitua
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Carolina Angélica Castillo Hernández
Universidad de Concepción, Chile

Antonio Cuadrado
Universidad Autónoma de Madrid

Violeta Durán Laforet
Universidad Complutense de Madrid

Tobias Engel
Royal College of Surgeons in Ireland, Dublin

Cristina Fernández Mendívil
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Alfonso Fernández-Mayoralas
CSIC, Madrid

Isabel Gameiro Ros
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Fernanda García Alvarado
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Justo García de Yébenes
Hospital Ramón y Cajal, Madrid

Yolanda Giménez Molina
Universidad Miguel Hernández, Elche, Spain

John Anthony Hardy
University College London, UK

Ricardo Henriques
University College London, UK

Aidan Kenny
RCSI PhD Physiology & Medical Physics Department 14-18
Royal College of Surgeons in Ireland

Arthur Konnerth
Technique Universitat Munchen, Germany

Fionna Martin
Eli Lilly and Company Limited, UK

Carmen Martínez Ramírez
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Iago Méndez López
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Patrycja Michalska
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Pilar Montero Ramos
CSIC, Madrid, Spain

Erwin Neher
Nobel Prize of Physiology or Medicine 1991

Vanesa Nozal García
Centro de Investigaciones Biológicas - CSIC

Carmen Pérez de Nanclares Fernández
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Sara Picó del Pino
Molecular Neurobiology Department
Centro de biología Molecular "Severo Ochoa"

Mariana Pires Antunes Alves
RCSI PhD Physiology & Medical Physics Department 14-18
Royal College of Surgeons in Ireland

Ana Belén Ramos Hryb
Universidade Federal de Santa Catarina, Brasil

Marcos Rubio Alarcón
Instituto Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Spain

Plamena Stroh
UCL Institute of Neurology, UK

Programa

Lunes, 25 Julio 2016

10:00
Inauguration
10:30
Inaugural Lecture
Glutamate release and short-term plasticity at the Calyx of Held synapse
Erwin Neher
12:00
Mitochondria as therapeutic targets in neurodegenerative diseases
Michael Duchen
15:00
YRC-1.- Purinergic receptors as targets for neuroprotection in neurodegenerative diseases
Evidence of internalization of Tau by microglia in tauopathies
Marta Bolós Jurado
The purinergic P2Y receptor family as novel drug targeting epilepsy
Mariana Pires Antunes Alves
RNA metabolism alterations in Huntington's disease
Sara Picó del Pino
MicroRNA Biomarkers in Alzheimer's Diagnostics
Aidan Kenny
Dual GSK3ß inhibitors and Nrf2 inducers: new multitarget and neuroprotective agents against Alzheimer's disease
Isabel Gameiro Ros
Coordinator
Tobias Engel

Martes, 26 Julio 2016

10:00
Neuronal impairments in Alzheimer's disease and emerging therapeutic strategies
Arthur Konnerth
12:00
Discovery of potent brain penetrant BACE inhibitors for Alzheimer's disease
Fionna Martin
15:00
YRC-2.-New ligands and drugs for brain disease
Chemoenzymatic preparation of chondroitin sulfates with a defined sulfatation pattern
Pilar Montero Ramos
Synthesis of novel Nrf2 inducers: pharmacological characterization and application for multiple sclerosis
Patrycja Michalska
Influence of microglial heme oxygenase-1 (HO-1) enzyme in inflammatory processes
Cristina Fernández Mendívil
ITH14001, a CGP37157 - nimodipine hybrid designed to regulate calcium homeostasis and oxidative stress, exerts neuroprotection in cerebral ischemia
Izaskun Buendía Abaitua
TTBK1 inhibitors, a promising approach for the treatment of neurodegenerative diseases
Vanesa Nozal García
Coordinator
Alfonso Fernández-Mayoralas

Miércoles, 27 Julio 2016

10:00
Democratising live-cell high-speed super-resolution microscopy
Ricardo Henriques
12:00
On being a Scientist
Erwin Neher
15:00
YRC-3.-Methods to explore synaptic transmission
Modulatory effects of Zinc on excitability of adrenal medullary rat slices
Andrés Mateo Baraibar Sierra
Role of nicotinic acetylcholine alpha 7 receptor in secretion in mouse chromaffin cells
Carmen Pérez de Nanclares Fernández
Confocal microscopy like a relevant tool to explore and understand the cellular cytoarchitecture under plasma membrane like a neurosecretion strategy in synaptic transmission
Yolanda Giménez Molina
Regulation by ER Ca2+ of the quantal catecholamine release in mouse chromaffin cells
Carmen Martínez Ramírez
Chromaffin cell of SOD1G93A mice show alterations in the cytoskeleton at presymptomatic ages
Iago Méndez López
Coordinator
Luis Gandía

Jueves, 28 Julio 2016

10:00
Targeting the transcription factor NRF2 for modification of Parkinson's disease progression
Antonio Cuadrado
12:00
Advances in the treatment of Parkinson's disease
Justo García de Yébenes
15:00
YRC-4.-New Therapeutic targets for neurodegenerative diseases
Drug repositioning for neuroprotection in Alzheimer's disease
Fernanda García Alvarado
The neuroprotective effect of a new isoform of Erythropoietin with low glycosilation on stress mediated by ß-amyloid peptide
Carolina Angélica Castillo Hernández
Delayed induction of vascular remodelling by acute artery recanalization in mice following stroke
Violeta Durán Laforet
New approach in the study of the mitochondrial Na+/Ca2+ exchanger (NCLX) blockers
Marcos Rubio Alarcón
Antidepressive and neuroprotective effects of ursolic acid in mice: in vivo and in vitro aproaches
Ana Belén Ramos Hryb
Non-antioxidant approach to fight oxidative damage in neurodegenerative diseases
Plamena Stroh
Coordinator
Antonio G. García

Viernes, 29 Julio 2016

10:00
The exocytotic fusion pore as an indicator of synaptic alterations in neurodegenerative diseases
Antonio G. García
11:30
Closing lecture: Genomic analysis of neurodegeneation
John Anthony Hardy
13:00
Closing ceremony